Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: India Globalization Capital, Inc.

Market Cap 26.34M 23.14M 21.32M 19.96M 37.4M 2.5B 38.03M 256M 99.1M 1.22B 98.88M 96.75M 4.25B P/E 2026 *
-2.96x
P/E 2027 * -3.33x
Enterprise Value 26.34M 23.14M 21.32M 19.96M 37.4M 2.5B 38.03M 256M 99.1M 1.22B 98.88M 96.75M 4.25B EV / Sales 2026 *
30.7x
EV / Sales 2027 * 25.6x
Free-Float
90.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 28/04/2005
Director of Finance/CFO 55 08/05/2018
Chief Operating Officer - 31/07/2019
Director TitleAgeSince
Chairman 67 28/04/2005
Director/Board Member 55 22/03/2022
Chairman 69 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+142.86%-47.69% - - 26.34M
+2.96%+4.08%-8.03%-2.24% 43.24B
+2.23%+8.26%+323.35%+564.22% 35.25B
+1.59%+4.63%+7.23%+54.02% 30.22B
+2.07%-4.40%+10.38%-19.99% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+4.64%+3.20% - - 14.16B
+3.91%+2.57%+53.41%+111.95% 13.01B
+2.77%+2.93%+9.65%+11.90% 12.7B
+0.13%+3.97%+101.73%+91.70% 12.54B
Average +15.81%-0.78%+62.70%+103.18% 23.69B
Weighted average by Cap. +1.60%-0.72%+69.07%+120.36%

Financials

2026 *2027 *
Net sales 857K 753K 694K 649K 1.22M 81.18M 1.24M 8.33M 3.22M 39.83M 3.22M 3.15M 138M 1.03M 904K 833K 779K 1.46M 97.43M 1.48M 10M 3.87M 47.8M 3.86M 3.78M 166M
Net income -8.78M -7.71M -7.11M -6.65M -12.47M -832M -12.68M -85.35M -33.04M -408M -32.96M -32.25M -1.42B -4.21M -3.7M -3.41M -3.19M -5.98M -399M -6.08M -40.94M -15.85M -196M -15.81M -15.47M -680M
Net Debt - -
Logo India Globalization Capital, Inc.
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!